特發性肺纖維化(IPF)市場：按藥物、給藥途徑、分銷渠道、區域-規模、份額、前景和機會分析，2023-2030年

特發性肺纖維化(IPF) 是一種原因不明的慢性疾病，主要影響老年人的肺部，與間質性肺炎(UIP) 的常見組織病理學和/或放射學模式相關。是一種特殊形式的進行性肺纖維化。纖維化間質性肺炎。 IPF 的診斷需要排除其他形式的間質性肺疾病，包括特發性間質性肺炎 (IIP) 和與環境暴露、藥物和結締組織疾病相關的間質性肺疾病 (ILD)。

市場動態

特發性肺纖維化（IPF）患病率的增加預計將推動市場增長。 例如，2021年7月，根據美國國家醫學圖書館發布的報告，2020年特發性肺纖維化（IPF）的患病率為全球每10萬人中13-20人。 2020年，美國將有約10萬人被確診，而每年新增確診人數為3萬至4萬人。

國家生物技術信息中心發布的一份報告發現，2021年印度特發性肺纖維化（IPF）的患病率約為13.7%。

此外，特發性肺纖維化 (IPF) 的患病率日益增加，促使主要市場參與者專注於新產品的推出，預計這將在預測期內推動市場增長。Masu。 例如，2022年5月，全球仿製藥和生物仿製藥領導者山德士宣布將與生物技術公司基因泰克旗下的Esbriett競爭特發性肺纖維化（IPF）患者的治療，並宣佈在美國上市□非尼酮，第一個AB級（抗體）（完全可替代）。 這種口服藥是通過專門的藥房給患者開的。

本研究的主要特點

• 本報告對全球特發性肺纖維化(IPF) 市場進行了深入分析，揭示了以2022 年為基準年的預測期（2023-2030 年）的市場規模和復合年增長率(CAGR% ) .) 已發布。
• 它揭示了各個細分市場的潛在收入機會，並概述了該市場有吸引力的投資主張矩陣。
• 它還提供了有關市場驅動因素、限制因素、機遇、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
• 它根據以下參數介紹了全球特發性肺纖維化 (IPF) 市場的領先企業 - 公司亮點、產品組合、主要亮點、財務業績、戰略。本研究涵蓋的主要公司包括Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical（India）Pvt Ltd, Sandoz International GmbH（Novartis）, and Algernon Pharmaceuticals Inc.等。
• 從本報告中獲得的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。 .
• 《全球特發性肺纖維化 (IPF) 市場報告》面向該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
• 利益相關者可以通過用於分析全球特發性肺纖維化 (IPF) 市場的各種策略矩陣來促進決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫

第 2 章市場展望

• 報告概述
  • 市場定義和範圍
• 執行摘要
• 連貫的機會地圖 (COM)

第 3 章市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 市場吸引力分析
  • 市場機會
  • 產品發布
  • 合併、收購與合作
  • 監管指南和合規性
  • 主要進展
  • 市場趨勢
  • PEST分析
  • 流行病學
  • 波特的分析
  • 監管場景
  • 品牌分析
  • 價格分析
  • 管道分析

第 4 章全球特發性肺纖維化 (IPF) 市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 經濟影響
• COVID-19 的流行病學特徵
• 對供需的影響

第 5 章 2017-2030 年特發性肺纖維化 (IPF) 全球市場（按代理商）

• □非尼酮
• 尼達尼布
• 其他（干擾素 gamma-1b、其他）

第 6 章按給藥途徑劃分的全球特發性肺纖維化 (IPF) 市場，2017-2030 年

• 口服劑
• 非口服藥

第 7 章 2017-2030 年特發性肺纖維化 (IPF) 全球市場（按分銷渠道）

• 醫院藥房
• 零售藥店
• 網上藥店

第 8 章2017-2030 年全球特發性肺纖維化 (IPF) 市場（按地區）

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 亞太地區其他地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第 9 章競爭格局

• Genentech, Inc.
• Boehringer Ingelheim International GmbH.
• Avalyn Pharma, Inc.
• AstraZeneca
• Blade Therapeutics
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche
• FibroGen, Inc.
• Galapagos NV
• MediciNova, Inc.
• Merck & Co., Inc.
• Promedior, Inc.
• Prometic Life Sciences Inc.
• Daewoong Pharmaceutical（India）Pvt Ltd
• Sandoz International GmbH（Novartis）
• Algernon Pharmaceuticals Inc.

第 10 章

• 調查方法
• 關於出版商

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies

Key features of the study:

• This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market

Detailed Segmentation:

• Global Idiopathic pulmonary fibrosis market, By Drug:
  • Pirfenidone
  • Nintedanib
  • Others (Interferon gamma-1b and Others)
• Global Idiopathic pulmonary fibrosis market, By Route of Administration:
  • Oral
  • Parenteral
• Global Idiopathic pulmonary fibrosis market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Idiopathic pulmonary fibrosis market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Genentech, Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim International GmbH
  • Avalyn Pharma, Inc.
  • AstraZeneca
  • Blade Therapeutics
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Hoffmann-La Roche
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • Prometic Life Sciences Inc.
  • Daewoong Pharmaceutical (India) Pvt Ltd
  • Sandoz International GmbH (Novartis)
  • Algernon Pharmaceuticals Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
  • Product Launches
  • Merger, Acquisition, Collaboration
  • Regulatory Guideline and Compliances
  • Key Developments
  • Market Trends
  • PEST Analysis
  • Epidemiology
  • PORTER's Analysis
  • Regulatory Scenario
  • Brand Analysis
  • Pricing Analysis
  • Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Pirfenidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Nintedanib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Interferon gamma-1b and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim International GmbH.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Avalyn Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Blade Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Galapagos NV
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• MediciNova, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Promedior, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prometic Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daewoong Pharmaceutical (India) Pvt Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sandoz International GmbH (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Algernon Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us